Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods (2023 - 2025)

Historic Finished Goods for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $9.3 million.

  • Krystal Biotech's Finished Goods rose 33805.27% to $9.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 million, marking a year-over-year increase of 33805.27%. This contributed to the annual value of $9.3 million for FY2025, which is 33805.27% up from last year.
  • Krystal Biotech's Finished Goods amounted to $9.3 million in Q4 2025, which was up 33805.27% from $7.3 million recorded in Q3 2025.
  • Krystal Biotech's Finished Goods' 5-year high stood at $9.3 million during Q4 2025, with a 5-year trough of $161000.0 in Q1 2024.
  • For the 3-year period, Krystal Biotech's Finished Goods averaged around $3.5 million, with its median value being $2.1 million (2024).
  • Data for Krystal Biotech's Finished Goods shows a peak YoY increase of 356335.4% (in 2025) and a maximum YoY decrease of 403.18% (in 2025) over the last 5 years.
  • Krystal Biotech's Finished Goods (Quarter) stood at $627000.0 in 2023, then soared by 239.07% to $2.1 million in 2024, then surged by 338.05% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q4 2025, $7.3 million for Q3 2025, and $1.7 million during Q2 2025.